GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population
暂无分享,去创建一个
Yang Dong | Chaoyin Jiang | Hua Chen | Lei Shao | Hua Chen | Chaoyin Jiang | Lei Shao | Yang Dong
[1] Ego Seeman,et al. Bone remodelling: its local regulation and the emergence of bone fragility. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[2] W. Wallace,et al. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. , 2007, The Journal of bone and joint surgery. British volume.
[3] M. Pearce,et al. Stature of young people with malignant bone tumors , 2004, Pediatric blood & cancer.
[4] D. Benayahu,et al. Cellular and molecular properties associated with osteosarcoma cells , 2001, Journal of cellular biochemistry.
[5] Silke Szymczak,et al. Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility , 2010, PloS one.
[6] A. Patiño-García,et al. Analysis of the human tumour necrosis factor-alpha (TNFα) gene promoter polymorphisms in children with bone cancer , 2000, Journal of medical genetics.
[7] Zhiming He,et al. Lysyl Oxidase Polymorphisms and Susceptibility to Osteosarcoma , 2012, PloS one.
[8] R. Hu,et al. Regulation of γ-aminobutyric acid (GABA) release in cerebral cortex in the γ-hydroxybutyric acid (GHB) model of absence seizures in rat , 2000, Neuropharmacology.
[9] Seung-Yong Jeong,et al. Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance , 2005, Clinical Cancer Research.
[10] R. Hayes,et al. Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. , 2010, Carcinogenesis.
[11] R. Kurzrock,et al. Phase 1 clinical trials for sarcomas: the cutting edge , 2011, Current opinion in oncology.
[12] Q. Wei,et al. Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients , 2007, Journal of pediatric hematology/oncology.
[13] William Stafford Noble,et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.
[14] G. Ottaviani,et al. The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.
[15] W. Rzeski,et al. Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.
[16] A. Buckley,et al. Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy , 2007, The Prostate.
[17] R. Gorlick. Current concepts on the molecular biology of osteosarcoma. , 2010, Cancer treatment and research.
[18] E. Kleinerman,et al. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[19] M. Joyce,et al. Bone sarcomas: Overview of management, with a focus on surgical treatment considerations , 2010, Cleveland Clinic Journal of Medicine.
[20] G. Schackert,et al. Glutamate receptors in pediatric tumors of the central nervous system , 2010, Cancer biology & therapy.
[21] E. Hinoi,et al. Glutamate signaling system in bone. , 2004, Journal of pharmacological sciences.
[22] Jinmin Zhao,et al. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[23] L. Liang,et al. A genome-wide association study of global gene expression , 2007, Nature Genetics.
[24] S. Chanock,et al. Analysis of Genes Critical for Growth Regulation Identifies Insulin-like Growth Factor 2 Receptor Variations with Possible Functional Significance as Risk Factors for Osteosarcoma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[25] R. Hayes,et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma , 2011, BMC Cancer.
[26] F. Baas,et al. Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma , 2012, PloS one.
[27] A. Patiño-García,et al. Analysis of Polymorphisms of the Vitamin D Receptor, Estrogen Receptor, and Collagen I&agr;1 Genes and Their Relationship With Height in Children With Bone Cancer , 2003, Journal of pediatric hematology/oncology.
[28] P. Picci,et al. Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival , 2009, Clinical Cancer Research.
[29] T. Triche,et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. , 2010, The Journal of clinical investigation.
[30] Jinmin Zhao,et al. Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma , 2014, Medical Oncology.
[31] R. Hoover,et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma , 2011, Cancer Causes & Control.
[32] S. Chanock,et al. Germ‐line genetic variation of TP53 in osteosarcoma , 2007, Pediatric blood & cancer.
[33] P. Genever,et al. Glutamate signalling in non-neuronal tissues. , 2001, Trends in pharmacological sciences.
[34] T. Takano,et al. Beyond the role of glutamate as a neurotransmitter , 2002, Nature Reviews Neuroscience.
[35] David M. Thomas,et al. Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma , 2013, Nature Genetics.
[36] F. Vannberg,et al. GENETICS OF GENE EXPRESSION IN PRIMARY IMMUNE CELLS IDENTIFIES CELL-SPECIFIC MASTER REGULATORS AND ROLES OF HLA ALLELES , 2012, Nature Genetics.
[37] L. Mirabello,et al. Using Epidemiology and Genomics to Understand Osteosarcoma Etiology , 2011, Sarcoma.
[38] Gurmit Singh,et al. Cancer cells release glutamate via the cystine/glutamate antiporter. , 2010, Biochemical and biophysical research communications.
[39] G. Bacci,et al. Height as a risk factor in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Koutsilieris,et al. Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. , 2004, Anticancer research.
[41] S. Bornstein,et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions , 2004, Journal of Medical Genetics.
[42] O. Snead,et al. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. , 1995, The Journal of pharmacology and experimental therapeutics.
[43] A. Temme,et al. Silencing of selected glutamate receptor subunits modulates cancer growth. , 2011, Anticancer research.
[44] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[45] T. Ueshima,et al. Glutamate signaling in peripheral tissues. , 2003, European journal of biochemistry.
[46] Yong Zhang,et al. Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.
[47] Zhaohui S. Qin,et al. A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.